SITAGLYN M 50/500 TAB

Distributor inventory | Tablet

Type 2 diabetes mellitus to improve blood glucose control along with diet and exercise; used when single therapy is inadequate.

Sitagliptin is a DPP-4 inhibitor that increases incretin levels, enhancing glucose-dependent insulin release and reducing glucagon secretion. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity, lowering blood glucose.

Take orally as prescribed, usually twice daily with meals to reduce stomach upset. Swallow tablet whole with water; do not crush/chew. Follow diet/exercise advice and monitor blood glucose regularly.

Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, metallic taste, headache, dizziness, upper respiratory tract infection, hypoglycaemia (especially with other antidiabetics)

Not for type 1 diabetes or diabetic ketoacidosis. Metformin may rarely cause lactic acidosis—risk increases with kidney impairment, dehydration, severe infection, heart/respiratory failure, liver disease, or heavy alcohol use; assess renal function before and during therapy. Temporarily stop metformin before/at time of iodinated contrast studies and major surgery; restart after renal function is stable. Pancreatitis and severe joint pain have been reported with sitagliptin—seek care for persistent severe abdominal pain. Use caution in elderly and in patients with renal impairment; dose adjustment may be needed based on eGFR.